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Translocations are one of the character-
istic genetic changes found in virtually all
hematopoietic and other malignancies.
Cloning of recurrent translocation break-
points and the identification of the native
genes involved has provided important
insights into the role of the fusion genes
in the process of malignant transforma-
tion. The genes participating in these
events are involved in the regulation of
differentiation, development, cell cycle,
and cell death. The fusion genes gener-
ated by translocations are selected in
tumors because their products have
acquired enhanced, unregulated, or
novel properties.
Translocations at 11q23 involve the
5′ end of the MLL gene which is fused to
one of a multitude of potential partners,
the identity of which determines the etiol-
ogy of the subsequent leukemia in
humans. While most of the MLL fusion
genes give rise to either a myeloid or a
mixed lineage leukemia, the transloca-
tion t(9:11) between the MLL and ENL
genes is unusual in promoting both
myeloid leukemia and a mixed
myeloid/lymphoid leukemia (Ayton and
Cleary, 2001). The mouse model devel-
oped for the MLL-ENL translocation
described by Forster et al. (2003) is strik-
ing in its genetic elegance and its ability
to model many key aspects of the human
disease.
The properties of leukemia-associat-
ed fusion genes have been examined in
a variety of ways in mice. The earliest
approaches used transgenic expression
of cDNA versions of these fusion genes
(Bernardi et al., 2002; Figure 1A).
Although the oncogenic properties of
some fusions can be demonstrated in
this way, the results are variable. The
fusion is often not expressed at the cor-
rect level or in the correct tissue com-
partment for disease development.
Overexpression of the fusion transgene
during development often results in
nonauthentic or lethal phenotypes that
invalidate or complicate the use of the
mouse line as a model for the intended
disease.
The use of the P1 phage derived
recombinase, Cre, for genetic manipula-
tion of mice has provided a means to
refine these crude transgenic models
(Kuhn and Torres, 2002). By expressing
Cre as a transgene, spatial and temporal
restrictions can be imposed so that the
expression of the fusion gene is limited
to compartments where both transgenes
are/were expressed. For example
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In this issue of Cancer Cell, Forster et al. (2003) have generated mice that recapitulate both the mechanism (sporadic somatic
translocation) and the consequences (expression of two translocation fusion genes) leading to an accurate leukemia model.
Figure 1. Expression of fusion genes using
fusion transgene, conditional fusion trans-
gene, and knockin fusion transgene
A: Fusion transgene. A fusion gene between
partners A and B can be used as a trans-
gene in mice. The spatial distribution, tempo-
ral activation, and level of expression of
germline copies of the transgene are
determined by the heterologous promot-
er/enhancer and the integration site(s) of
the transgene.
B: Conditional fusion transgene. The activity
of the fusion transgene can be refined by
making it dependent on the expression of
Cre. The fusion transgene is not expressed
until the transcriptional stop cassette
between the promoter and fusion gene is
deleted by Cre, determined by its heterolo-
gous promoter. loxP sites are shown as red tri-
angles.
C: Knockin fusion gene. A fusion gene can
be generated in the appropriate chromoso-
mal context of one partner (gene A) by
“knocking in” the appropriate part of the
fusion partner (gene B) into the genomic
locus of gene A. The fusion gene is present in
the germline, and its expression during
development can lead to developmental
abnormalities.
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(Figure 1B), expression of Cre leads to
deletion of a transcriptional stop
sequence between a fusion transgene
and its promoter. This enables mice to
proceed through embryogenesis with
certain transgenes that cause develop-
mental problems. However, in the tissues
in which Cre is expressed, the transgene
may still be expressed in an unregulated
way.
The deficiencies of randomly inte-
grated transgenic constructs have been
largely overcome with the development
of embryonic stem cell technology. A
fusion gene(s) can be constructed in 
an appropriate chromosomal context
(Figure 1C). This is most readily
achieved by targeting (knocking in) the 3′
part of the fusion gene into the genomic
locus of the other partner. Although such
an allele is likely to be expressed at the
appropriate level, it can be difficult to
transmit this type of allele into the mouse
germline, because of the developmental
problems caused by activity of the fusion
gene in an entire tissue compartment
(Corral et al., 1996). This can be over-
come if the fusion gene can be condition-
ally activated with Cre (Figure 2A).
All of these transgenic and targeting
approaches suffer from one major limita-
tion; namely, they produce a field of cells
expressing the fusion gene within a spe-
cific tissue compartment. However, can-
cer develops in an entirely different way:
a single cell which undergoes a translo-
cation will clonally expand in a microen-
vironment which is initially composed of
normal cells.
A more normal “physiological” cellu-
lar context can be achieved by transduc-
ing bone marrow progenitor cells with the
relevant transgene and transferring them
back into the mouse to develop in vivo
(Figure 2B). This approach has been
successfully employed to model MLL-
associated translocations. Pertinent to
the current study, this approach has
recently been applied to the Mll-Enl
fusion gene (Zeisig et al., 2003).
Syngeneic mice receiving transduced
bone marrow cells developed an aggres-
sive disease. This technique has the
added advantage that the mixed lym-
phoid/myeloid component of the human
leukemia can be artificially modeled by
inducing the lymphoid differentiation
pathway by treating the transduced cells
with flt3 ligand.
Forster et al. (2003) have solved this
problem in a different and altogether
more elegant way, and in doing so have
taken cancer modeling to a new mecha-
nistic level (Figure 2C). In their experi-
ments, loxP sites were targeted to
positions in the mouse corresponding to
the breakpoint observed in MLL and ENL
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Figure 2. Expression of fusion genes using
conditional knockin fusion gene, retroviral
transduction of haematopoetic progenitor
cells, and de novo reciprocal chromosomal
translocation
A: Conditional knockin fusion gene. An addi-
tional layer of temporal and spatial control
of the activity of a knockin fusion can be pro-
vided by a Cre transgene. The knockin fusion
is not expressed until the “stop” cassette is
removed by the activity of Cre, determined
by a heterologous promoter. loxP sites are
shown as red triangles.
B: Transduction of haematopoetic progeni-
tor cells with retrovirus particles containing
the fusion gene expression cassette in vitro.
The transduced cells can be returned to
adult mice in appropriate numbers and at a
relevant time, avoiding many of the issues of
inappropriate temporal expression.
C: Cre mediated interchromosomal translo-
cation between loxP sites (red triangles) tar-
geted to the desired breakpoint point
positions. Both fusion gene partners are
induced in authentic chromosomal loca-
tions. An appropriately expressed Cre trans-
gene limits the translocation to an
appropriate cellular compartment and the
events are relatively rare, recapitulating the
sporadic nature of translocation events in
human cancer.
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in human leukemia. They have utilized
Cre to recombine loxP sites placed on
different chromosomes (Van Deursen et
al., 1995; Smith et al., 1995). This juxta-
position of genetic elements creates rec-
iprocal fusion genes at the breakpoints in
the context of their natural loci and under
transcriptional control of their authentic
promoters.
Although previous studies had indi-
cated the ability to effect such de novo
translocations within mice, disease phe-
notypes were not observed, ascribed by
the authors to inappropriate levels and
distribution of Cre transgene expression
(Bucholz et al., 2000; Collins et al.,
2000). The hematopoietic lineage
expression of the lmo-2 Cre knockin
mouse has the appropriate expression
characteristics for use with the Mll-Enl
translocation induction within the
myeloid lineage. Expression of Cre leads
to rapid onset, highly penetrant leukemo-
genesis, which is always associated with
the induced translocation event.
However, the mouse model only devel-
oped the myeloid component of the dis-
ease, with no evidence of lymphoid
lineage markers being detected in
leukemic cells.Whether the lack of mixed
lymphoid/myeloid leukemia in these
mice represents a technical inadequacy
in the system or a basic difference in
biology between mouse and man
remains to be seen.
Although this study is of undoubted
significance to understanding the devel-
opment and potential treatment of this
particular form of leukemia, the real high-
light is its technical elegance and the
likely applicability to the whole range of
leukemias and sarcomas that develop as
a consequence of chromosomal translo-
cations (Bernardi et al., 2002). This is
because it accurately replicates all of the
functional events that lead to the devel-
opment of the analogous human tumor:
(1) the translocation occurs somatically,
rather than being present throughout
development; (2) the translocation
occurs exclusively within a defined tissue
compartment where the tumor develops
in human; and (3) the translocation pro-
duces fusion genes at the two chromo-
somal breakpoints that accurately
replicate those in the human cancer, as it
is possible that either one, or indeed
both, of the fusion genes might con-
tribute to various aspects of disease
development (Rego and Pandolfi, 2002).
The judicious choice and empirical
development and testing of Cre-express-
ing mouse lines may allow similar devel-
opment of de novo translocation models
for a whole range of different endpoints
with specific target disease tissues.
There is one real limitation to this
technique for modeling human transloca-
tions. Regions in the mouse genome
which correspond to translocation end-
points in humans are not always in the
same orientation with respect to the cen-
tromere.To avoid the creation of aberrant
dicentric chromosomes, comparison of
human and mouse genome sequences
is essential to assess applicability of the
technique to individual cases. In cases
where the genes are not appropriately
aligned, it is possible to invert one or
other chromosome using chromosome
engineering technology (Zheng et al.,
1999), thus recreating the human chro-
mosomal context.
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